Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diastereomer 2. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR known ✓ | Q13258 | 15/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 13/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 5/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 3/20 | 1.00 |
| ▸ | PTGIR | P43119 | 3/20 | 1.00 |
| ▸ | PTGER1 | P34995 | 2/20 | 1.00 |
| ▸ | PTGFR | P43088 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | TSPO | P30536 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 1.00 |
| ▸ | PDE2A | O00408 | 7/20 | 0.90 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Laropiprant SCHEMBL991107 | 1.00 | PTGDR (1.00) | PTGDRTBXA2RPTGER2PTGER3PTGIR | |
| Laropiprant SCHEMBL29612617 | 1.00 | PTGDR (1.00) | PTGDRTBXA2RPTGER2PTGER3PTGIR | |
| Diastereomer 2 SCHEMBL32668949 | 1.00 | PTGDR (1.00) | PTGDRTBXA2RPTGER2PTGER3PTGIR | |
| SCHEMBL991121 | 0.95 | PTGDR (1.00) | PTGDRTBXA2RPTGER2PTGER3PTGIR | |
| SCHEMBL4548354 | 0.95 | PTGDR (1.00) | PTGDRTBXA2RPTGER2PTGER3PTGIR | |
| SCHEMBL13344157 | 0.93 | PTGDR (0.86) | PTGDRTBXA2RPTGER2PTGER3PTGIR | |
| SCHEMBL19799336 | 0.93 | PTGDR (0.86) | PTGDRTBXA2RPTGER2PTGER3PTGIR | |
| SCHEMBL13344139 | 0.93 | PTGDR (0.86) | PTGDRTBXA2RPTGER2PTGER3PTGIR | |
| Laropiprant SCHEMBL29398067 | 0.89 | PTGDR (0.80) | PTGDRTBXA2RPTGER2PTGER3PTGIR | |
| SCHEMBL19861546 | 0.89 | PTGDR (0.80) | PTGDRTBXA2RPTGER2PTGER3PTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295409-B1 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2014-07-02 | — | — | EP | claimed |
| EP-2295409-A1 | Fluoro substituted cycloalkanoindoles and their use as prostaglandin D2 receptor antagonists | Merck Frosst Canada Limited (CA) | 2011-03-16 | — | — | EP | claimed |
| EP-1470107-B1 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2008-11-19 | — | — | EP | claimed |
| US-20080033028-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | BERTHELETTE CARL | 2008-02-07 | — | — | US | claimed |
| US-20060069148-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | BERTHELETTE CARL | 2006-03-30 | — | — | US | claimed |
| US-20050124680-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | MERCK CANADA INC. (CA) | 2005-06-09 | — | — | US | claimed |
| EP-1470107-A2 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Merck Frosst Canada & Co. (CA) | 2004-10-27 | — | — | EP | claimed |
| US-20030158246-A1 | For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis. | MERCK FROSST CANADA & CO. (CA) | 2003-08-21 | — | — | US | claimed |
| WO-2003062200-A2 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA & CO. (CA) | 2003-07-31 | — | — | WO | claimed |
| US-12589089-B2 | PTGDR-1 and/or PTGDR-2 antagonists for preventing and/or treating systemic lupus erythematosus | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-03-31 | — | — | US | disclosed |
| US-20250017900-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | UNIVERSITÉ PARIS CITÉ (FR) | 2025-01-16 | — | — | US | disclosed |
| EP-4420734-A2 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-08-28 | — | — | EP | disclosed |
| EP-3256121-B1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | INST NAT SANTE RECH MED (FR) | 2024-08-07 | — | — | EP | disclosed |
| US-20230330062-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | INST NAT SANTE RECH MED (FR) | 2023-10-19 | — | — | US | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070244107-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | MERCK & CO., INC. | 2007-10-18 | — | — | US | disclosed |
| US-20060069148-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | BERTHELETTE CARL | 2006-03-30 | — | — | US | disclosed |
| US-20050124680-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | MERCK CANADA INC. (CA) | 2005-06-09 | — | — | US | disclosed |
| US-20040229844-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | CHENG KANG (US) | 2004-11-18 | — | — | US | disclosed |
| US-20030158246-A1 | For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis. | MERCK FROSST CANADA & CO. (CA) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017900-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | PTGDR, PTGDR2, PTGIR | PTGDR 1/4885TBXA2R 16/4885PTGER2 8/4885 |
| US-20060069148-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | PTGER1, PTGER3, PTGER2 | PTGDR 7/4885TBXA2R 17/4885PTGER2 3/4885 |
| US-20030158246-A1 | For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis. | PTGES, PTGIR, PTGER1 | PTGDR 14/4885TBXA2R 25/4885PTGER2 5/4885 |
| US-20050124680-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | PTGER1, PTGER3, PTGER2 | PTGDR 7/4885TBXA2R 17/4885PTGER2 3/4885 |
| US-20080033028-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | PTGER1, PTGER3, PTGER2 | PTGDR 7/4885TBXA2R 17/4885PTGER2 3/4885 |
| US-12589089-B2 | PTGDR-1 and/or PTGDR-2 antagonists for preventing and/or treating systemic lupus erythematosus | PTGIR, PTGDR, SSB | PTGDR 2/4885TBXA2R 13/4885PTGER2 14/4885 |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | LDLR, APOB, FFAR1 | PTGDR 591/4885TBXA2R 44/4885PTGER2 466/4885 |
| US-20230330062-A1 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | PTGDR2, PTGDR, PTGIR | PTGDR 2/4885TBXA2R 10/4885PTGER2 9/4885 |
| US-20070244107-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions | LDLR, LIPA, APOB | PTGDR 97/4885TBXA2R 68/4885PTGER2 223/4885 |
| US-20040229844-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | LDLR, HCAR1, FFAR1 | PTGDR 201/4885TBXA2R 37/4885PTGER2 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.